US Patent 11180551 Humanized monoclonal antibodies that target VE-PTP (HPTP-beta)
Patent 11180551 was granted and assigned to EyePoint Pharmaceuticals on November, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 25 Jul, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
0
Edits on 19 Jan, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+228 characters)
Article
Patent abstract
The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.
Edits on 21 Jul, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 22 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
111805510
Date of Patent
November 23, 2021
0Patent Application Number
168514200
Date Filed
April 17, 2020
0Official Website
Patent Primary Examiner
Edits on 24 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
111805510
Date of Patent
November 23, 2021
0Patent Application Number
168514200
Date Filed
April 17, 2020
0Official Website
Patent Primary Examiner
Edits on 17 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 25 Nov, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 11180551 Humanized monoclonal antibodies that target VE-PTP (HPTP-beta)
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
11180551
Date of patent
November 23, 2021
Patent application number
16851420
Date Filed
April 17, 2020
Patent primary examiner
Find more entities like US Patent 11180551 Humanized monoclonal antibodies that target VE-PTP (HPTP-beta)
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
